0001104659-18-045040.txt : 20180814 0001104659-18-045040.hdr.sgml : 20180814 20180713153511 ACCESSION NUMBER: 0001104659-18-045040 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180713 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rubius Therapeutics, Inc. CENTRAL INDEX KEY: 0001709401 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 042688109 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 325 VASSAR STREET, SUITE 1A CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-679-9600 MAIL ADDRESS: STREET 1: 325 VASSAR STREET, SUITE 1A CITY: CAMBRIDGE STATE: MA ZIP: 02139 CORRESP 1 filename1.htm

 

VIA EDGAR

 

July 13, 2018

 

U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

 

Attn:                    Mary Beth Breslin
Jeffrey Gabor

 

Re:                             Rubius Therapeutics, Inc.

Acceleration Request for Registration Statement on Form S-1

File No. 333-225840

 

Requested Date:

July 17, 2018

Requested Time:

4:00 p.m. Eastern Standard Time

 

Dear Ms. Breslin and Mr. Gabor:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Rubius Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to July 17, 2018, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time.  In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

 

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Arthur R. McGivern at (617) 570-1971. We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the “Commission”) verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Arthur R. McGivern, by facsimile to (617) 801-8626.

 


 

If you have any questions regarding this request, please contact Arthur R. McGivern of Goodwin Procter LLP at (617) 570-1971.

 

 

Sincerely,

 

 

 

RUBIUS THERAPEUTICS, INC.

 

 

 

 

 

/s/ Pablo J. Cagnoni

 

Pablo J. Cagnoni

 

Chief Executive Officer

 

 

 

 

cc:

Andrew M. Oh, Chief Financial Officer, Rubius Therapeutics, Inc.

 

Stuart M. Cable, Esq., Goodwin Procter LLP

 

Arthur R. McGivern, Esq., Goodwin Procter LLP